Exercise of Procurement Options of Approximately $113m for Oral TPOXX and Approximately $25m for IV TPOXX under Current Contract reflects continuing global action to enhance smallpox preparedness
the headquarters building of the U.S. Department of Health and Human Services. (Credit: Carol M. Highsmith from Wikimedia Commons)
SIGA Technologies, a commercial-stage pharmaceutical company, today announced that the U.S. Department of Health and Human Services exercised procurement options for the delivery of approximately $113m worth of oral TPOXX treatment courses and approximately $25m worth of IV TPOXX treatment courses.
“Building on the orders SIGA received for TPOXX from 13 international customers and the US Department of Defense in 2022, these most recent procurement orders further highlight that many global leaders in public heath recognize the importance of orthopoxvirus preparedness and the need to take action to keep people safe,” said Phil Gomez, CEO of SIGA. “We are pleased that we are able to consistently meet demand for oral TPOXX, which is driving substantial and increasingly diversified global revenue opportunities at SIGA.”
SIGA expects to fully deliver approximately $113m of oral TPOXX under this order in 2023 and expects to start delivering IV TPOXX under this order in 2024. Prior to delivery of IV TPOXX under this order, SIGA will be focused on fulfilling delivery obligations under a prior IV TPOXX order.
This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) and Strategic National Stockpile, under Contract No. 75A50118C00019.
Source: Company Press Release